Psoriasis: what we have learned from mouse models
- PMID: 20877306
- DOI: 10.1038/nrrheum.2010.157
Psoriasis: what we have learned from mouse models
Abstract
Psoriasis is a common inflammatory skin disease of unknown etiology, for which there is no cure. This heterogeneous, cutaneous, inflammatory disorder is clinically characterized by prominent epidermal hyperplasia and a distinct inflammatory infiltrate. Crosstalk between immunocytes and keratinocytes, which results in the production of cytokines, chemokines and growth factors, is thought to mediate the disease. Given that psoriasis is only observed in humans, numerous genetic approaches to model the disease in mice have been undertaken. In this Review, we describe and critically assess the mouse models and transplantation experiments that have contributed to the discovery of novel disease-relevant pathways in psoriasis. Research performed using improved mouse models, combined with studies employing human cells, xenografts and patient material, will be key to our understanding of why such distinctive patterns of inflammation develop in patients with psoriasis. Indeed, a combination of genetic and immunological investigations will be necessary to develop both improved drugs for the treatment of psoriasis and novel curative strategies.
Similar articles
-
Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model.Nat Med. 2005 Jan;11(1):43-9. doi: 10.1038/nm1162. Epub 2004 Dec 12. Nat Med. 2005. PMID: 15592573
-
Animal models of psoriasis.Clin Dermatol. 2007 Nov-Dec;25(6):596-605. doi: 10.1016/j.clindermatol.2007.08.014. Clin Dermatol. 2007. PMID: 18021898 Review.
-
[Advances in pathogenesis of psoriasis].Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006 Nov;35(6):673-7. doi: 10.3785/j.issn.1008-9292.2006.06.018. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006. PMID: 17177343 Review. Chinese.
-
Keratinocytes regain momentum as instigators of cutaneous inflammation.Trends Mol Med. 2006 Mar;12(3):102-6. doi: 10.1016/j.molmed.2006.01.001. Epub 2006 Jan 27. Trends Mol Med. 2006. PMID: 16443394
-
Psoriasis: the epidermal component.Clin Dermatol. 2007 Nov-Dec;25(6):589-95. doi: 10.1016/j.clindermatol.2007.09.021. Clin Dermatol. 2007. PMID: 18021897 Review.
Cited by
-
An Anti-Inflammatory Poly(PhosphorHydrazone) Dendrimer Capped with AzaBisPhosphonate Groups to Treat Psoriasis.Biomolecules. 2020 Jun 23;10(6):949. doi: 10.3390/biom10060949. Biomolecules. 2020. PMID: 32586038 Free PMC article.
-
Indoleamine 2,3-Dioxygenase 2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation.Int J Mol Sci. 2020 Aug 1;21(15):5515. doi: 10.3390/ijms21155515. Int J Mol Sci. 2020. PMID: 32752186 Free PMC article.
-
Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders.J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1111-1119. doi: 10.1111/jdv.14868. Epub 2018 Mar 9. J Eur Acad Dermatol Venereol. 2018. PMID: 29438576 Free PMC article. Review.
-
Immune responses and therapeutic options in psoriasis.Cell Mol Life Sci. 2021 Mar;78(6):2709-2727. doi: 10.1007/s00018-020-03726-1. Epub 2021 Jan 2. Cell Mol Life Sci. 2021. PMID: 33386888 Free PMC article. Review.
-
Psoriasiform skin disease in transgenic pigs with high-copy ectopic expression of human integrins α2 and β1.Dis Model Mech. 2017 Jul 1;10(7):869-880. doi: 10.1242/dmm.028662. Dis Model Mech. 2017. PMID: 28679670 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical